# Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

> **NCT01176006** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- DOCK8 Deficiency

## Interventions

- **PROCEDURE:** Reduced-intensity hematopoietic stem cell
- **DRUG:** Fludarabine(Fludara, Berlex Laboratories)
- **DRUG:** Cyclophosphamide(CTX, Cytoxan)
- **PROCEDURE:** Total Body Irradiation (TBI)
- **DRUG:** Busulfan (Busulfex)
- **PROCEDURE:** Donor peripheral blood stem cell mobiliation and collection
- **PROCEDURE:** Bone Marrow Harvest Procedure

## Key facts

- **NCT ID:** NCT01176006
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-10-05
- **Primary completion:** 2026-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176006, "Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01176006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*